Maximize Investigator Initiated Studies
March 21 – 22, 2005 Philadelphia, PA
Visit the conference website for more information and to register.
Once a product is approved companies can get inundated with requests from investigators wanting to conduct independent studies using the approved drugs. Pharmaceutical companies view these studies as important vehicles to educate the medical community about the new uses of their drugs, safety issues and the efficacy of their drugs. However with post marketing budgets continuing to be cut it is important for companies to make strategic investments in these studies. The objective of this conference is to provide attendees with strategic business solutions to improving investigator initiated studies.
CBIs Premier Forum on Maximize Investigator Initiated Studies, March 21 – 22, 2005, provides you with the opportunity to hear case studies from industry leaders on the challenges theyve faced, solutions they developed and successes theyve had in maximizing Investigator Initiated Studies. Hear key address on proposal development, data protection, investigator qualification and medical science liaisons in the IIS process and much more!
Attend this conference to:
- Identify key criterias for qualifying investigators
- Learn best methods for monitoring the process and progress of the investigator initiated study
- Discover ways for assuring that results are published
13 industry perspectives from the following companies:
Abbott Laboratories * AstraZeneca * Bayer * Berlex * Biogen Idec * Celegene Corporation * Intermune * Organon Pharmaceuticals * Sanofi Synthelabo * Wyeth PharmaceuticalsFor more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at email@example.com or visit the conference website.